Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma

Marina Bagnoli, Giovanni L. Beretta, Laura Gatti, Silvana Pilotti, Paola Alberti, Eva Tarantino, Mattia Barbareschi, Silvana Canevari, Delia Mezzanzanica, Paola Perego

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Ovarian cancer is the main cause of death from gynaecological malignancies. In spite of the efficacy of platinum-paclitaxel treatment in patients with primary epithelial ovarian carcinoma, platinum-based chemotherapy is not curative and resistance remains one of the most important causes of treatment failure. Although ABC transporters have been implicated in cellular resistance to multiple drugs, the clinical relevance of these efflux pumps is still poorly understood. Thus, we examined the prognostic role of transporters of the MRP family (i.e., ABCC1/MRP1, ABCC4/MRP4) to gain insights into their clinical impacts. A case material of 127 patients with ovarian carcinoma at different stages and histotypes was used. The expression of MRP1 and MRP4 was examined by immunohistochemistry using tissue microarrays in tumor specimens collected at the time of initial surgery expression. We found an association between MRP1 expression and grading, and we observed that MRP4 displayed an unfavourable impact on disease relapse in multivariate analysis (HR = 2.05, 95% CI: 1.01-4.11; P = 0.045). These results suggest that in epithelial ovarian cancer, MRP1 may be a marker for aggressiveness because its expression was associated with tumor grade and support that MRP4 may play an unfavourable role in disease outcome.

Original languageEnglish
Article number143202
JournalBioMed Research International
Volume2013
DOIs
Publication statusPublished - 2013

Fingerprint

Platinum
Tumors
Carcinoma
ATP-Binding Cassette Transporters
Chemotherapy
Microarrays
Paclitaxel
Surgery
Neoplasms
Association reactions
Multiple Drug Resistance
Pumps
Tissue
Treatment Failure
Ovarian Neoplasms
Cause of Death
Multivariate Analysis
Immunohistochemistry
Pharmaceutical Preparations
Recurrence

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma. / Bagnoli, Marina; Beretta, Giovanni L.; Gatti, Laura; Pilotti, Silvana; Alberti, Paola; Tarantino, Eva; Barbareschi, Mattia; Canevari, Silvana; Mezzanzanica, Delia; Perego, Paola.

In: BioMed Research International, Vol. 2013, 143202, 2013.

Research output: Contribution to journalArticle

Bagnoli, Marina ; Beretta, Giovanni L. ; Gatti, Laura ; Pilotti, Silvana ; Alberti, Paola ; Tarantino, Eva ; Barbareschi, Mattia ; Canevari, Silvana ; Mezzanzanica, Delia ; Perego, Paola. / Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma. In: BioMed Research International. 2013 ; Vol. 2013.
@article{98739939acfc47029a85357ecfae382f,
title = "Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma",
abstract = "Ovarian cancer is the main cause of death from gynaecological malignancies. In spite of the efficacy of platinum-paclitaxel treatment in patients with primary epithelial ovarian carcinoma, platinum-based chemotherapy is not curative and resistance remains one of the most important causes of treatment failure. Although ABC transporters have been implicated in cellular resistance to multiple drugs, the clinical relevance of these efflux pumps is still poorly understood. Thus, we examined the prognostic role of transporters of the MRP family (i.e., ABCC1/MRP1, ABCC4/MRP4) to gain insights into their clinical impacts. A case material of 127 patients with ovarian carcinoma at different stages and histotypes was used. The expression of MRP1 and MRP4 was examined by immunohistochemistry using tissue microarrays in tumor specimens collected at the time of initial surgery expression. We found an association between MRP1 expression and grading, and we observed that MRP4 displayed an unfavourable impact on disease relapse in multivariate analysis (HR = 2.05, 95{\%} CI: 1.01-4.11; P = 0.045). These results suggest that in epithelial ovarian cancer, MRP1 may be a marker for aggressiveness because its expression was associated with tumor grade and support that MRP4 may play an unfavourable role in disease outcome.",
author = "Marina Bagnoli and Beretta, {Giovanni L.} and Laura Gatti and Silvana Pilotti and Paola Alberti and Eva Tarantino and Mattia Barbareschi and Silvana Canevari and Delia Mezzanzanica and Paola Perego",
year = "2013",
doi = "10.1155/2013/143202",
language = "English",
volume = "2013",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma

AU - Bagnoli, Marina

AU - Beretta, Giovanni L.

AU - Gatti, Laura

AU - Pilotti, Silvana

AU - Alberti, Paola

AU - Tarantino, Eva

AU - Barbareschi, Mattia

AU - Canevari, Silvana

AU - Mezzanzanica, Delia

AU - Perego, Paola

PY - 2013

Y1 - 2013

N2 - Ovarian cancer is the main cause of death from gynaecological malignancies. In spite of the efficacy of platinum-paclitaxel treatment in patients with primary epithelial ovarian carcinoma, platinum-based chemotherapy is not curative and resistance remains one of the most important causes of treatment failure. Although ABC transporters have been implicated in cellular resistance to multiple drugs, the clinical relevance of these efflux pumps is still poorly understood. Thus, we examined the prognostic role of transporters of the MRP family (i.e., ABCC1/MRP1, ABCC4/MRP4) to gain insights into their clinical impacts. A case material of 127 patients with ovarian carcinoma at different stages and histotypes was used. The expression of MRP1 and MRP4 was examined by immunohistochemistry using tissue microarrays in tumor specimens collected at the time of initial surgery expression. We found an association between MRP1 expression and grading, and we observed that MRP4 displayed an unfavourable impact on disease relapse in multivariate analysis (HR = 2.05, 95% CI: 1.01-4.11; P = 0.045). These results suggest that in epithelial ovarian cancer, MRP1 may be a marker for aggressiveness because its expression was associated with tumor grade and support that MRP4 may play an unfavourable role in disease outcome.

AB - Ovarian cancer is the main cause of death from gynaecological malignancies. In spite of the efficacy of platinum-paclitaxel treatment in patients with primary epithelial ovarian carcinoma, platinum-based chemotherapy is not curative and resistance remains one of the most important causes of treatment failure. Although ABC transporters have been implicated in cellular resistance to multiple drugs, the clinical relevance of these efflux pumps is still poorly understood. Thus, we examined the prognostic role of transporters of the MRP family (i.e., ABCC1/MRP1, ABCC4/MRP4) to gain insights into their clinical impacts. A case material of 127 patients with ovarian carcinoma at different stages and histotypes was used. The expression of MRP1 and MRP4 was examined by immunohistochemistry using tissue microarrays in tumor specimens collected at the time of initial surgery expression. We found an association between MRP1 expression and grading, and we observed that MRP4 displayed an unfavourable impact on disease relapse in multivariate analysis (HR = 2.05, 95% CI: 1.01-4.11; P = 0.045). These results suggest that in epithelial ovarian cancer, MRP1 may be a marker for aggressiveness because its expression was associated with tumor grade and support that MRP4 may play an unfavourable role in disease outcome.

UR - http://www.scopus.com/inward/record.url?scp=84884234071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884234071&partnerID=8YFLogxK

U2 - 10.1155/2013/143202

DO - 10.1155/2013/143202

M3 - Article

VL - 2013

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 143202

ER -